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ABSTRACT 
The present study on the manufacturing of Microballons of Domperidone elaborates various steps taken during the development a nd 
manufacturing of microballoons keeping in constant knowledge of quality by design guidelines. The importance of target product profile and 
critical quality attributes which results in the finalization of product design have been demonstrated in the present work. Every steps were 
taken after due consideration of risk evolved by virtue of prior technical knowledge and experimentation. In the product design space the 
product characterization involved critical quality attributes which ultimately leads to critical process parameters that are design space. Control 
strategies for continuous monitoring process and product have also been recommended. Critical process parameters were also validated to 
achieve and monitor the quality of final product. The CPP has direct impact on critical quality attributes hence these parameters were develop 
with proper tolerances. The QbD principle demonstrated in present research will play an important role in the understanding a nd creating 
opportunities for investigation and control strategy in formulation and process development. 
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INTRODUCTION 
Conventional oral dosage forms such as tablets, capsules 
provide a specific drug concentration in systemic circulation 
which do not release at the constant rate for prolonged 
period of time. Controlled release drug delivery system 
(CRDDS) provides drug release at a precontrolled, 
predictable rate either systematically or locally for intended 
duration of time and optimizes the therapeutic effect of a 
drug by controlling its release into the body with lower and 
less frequent dosing1 
Gastroretentive drug delivery systems (GRDDS)  
Dosage forms that can be retained in stomach for longer 
periods of time are called gastroretentive drug delivery 
systems (GRDDS).  
GRDDS are suitable and beneficial for such drugs by 
improving their absolute bioavailability, therapeutics 
efficiency, increase gastric residence time (GRT), possible 
reduction of the dose, reduces drug waste and improves 
solubility for drugs that are less soluble in a high pH 
environment. 
Floating drug delivery system  
Many floating systems have been generated based on 
granules, powders, capsules, tablets, laminated films, beads 
and hollow microspheres2,3.  
It can be classified into two systems:4,5  
Effervescent System  
Volatile liquid containing systems (Intragastric floating 
GRDDS) Gas-generating Systems (Intra gastric single layer 
and bilayered floating tablets, Multiple unit type floating 
pills)  
Non-Effervescent Systems  
Hydro colloidal gel barrier systems  
Micro porous compartment system  
Alginate and pectin beads  
Hollow microsphere (Microballoons)  
Microballoons are gastro retentive drug-delivery systems 
with non-effervescent approach. Microballoons (Hollow 
microsphere) are in strict sense, empty particles of spherical 
shape without core. These microspheres are 
characteristically free flowing powders comprising of 
proteins or synthetic polymers, ideally having a size less than 
200 micrometer6.  
Microballoons are considered as one of the most favourable 
buoyant systems with the unique advantages of multiple unit 
systems as well as better floating properties, because of 
central hollow space inside the microsphere. The slow 
release of drug at desired rate and better floating properties 
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mainly depend on the type of polymer, plasticizer and the 
solvents employed for the preparation. Polymers such as 
polylactic acid, Eudragit® S and hydroxy propyl methyl 
cellulose cellulose acetate are used in the formulation of 
hollow microspheres, and the release of drug can be 
modulated by optimizing polymer concentration and the 
polymer -plasticizer ratio7.  
Hollow microspheres / microballoons loaded with drug in 
their outer polymer shell are prepared by a novel methods 
such as solvent evaporation or solvent diffusion/evaporation 
to create a hollow inner core. The drug and an enteric acrylic 
polymer mixture is dissolved in ethanol/dichloromethane 
solution and it is poured into an agitated solution of Poly 
Vinyl Alcohol (PVA) that as thermally controlled at 40 ºC. 
After the formation of stable emulsion, the organic solvent is 
evaporated from the emulsion by increasing the temperature 
under pressure or by continuous stirring8. The gas phase is 
generated in the droplet of dispersed polymer by the 
evaporation of dichloromethane and thus formed the hollow 
internal cavity in the microsphere of the polymer with drug. 
The microballoon is continuously float over the surface of an 
acidic dissolution media containing surfactant for more than 
12 hours9,10. 
MATERIALS AND METHODS 
       Table No. 1: Name of Materials 
Sr. 
No. 
Name of 
Materials 
Supplied By/Gifted By 
 
1 Domperidone Research Lab. Fine Chem Industries 
Mumbai 
2 Ethanol Sahyadri Scientific Research Islampur 
3 Dichloro 
methane 
Sahyadri Scientific Research Islampur 
4 HPMC Sahyadri Scientific Research Islampur 
5 Eudragit Sahyadri Scientific Research Islampur 
6 PVA Sahyadri Scientific Research Islampur 
Inactive ingredient profile 
Table No. 2 Inactive Ingedient Guide limit 
Sr. 
No. 
Name of 
Inactive 
Ingredients 
Quantity 
Taken 
Per Tablet 
Maximum 
quantity as per 
IIG for 
Immediate 
Release Tablet 
1. Eudragit RS 9 mg 15mg 
2. HPMC 1mg 4 mg 
3. Ethanol 5ml 12ml 
4. Dichloromethane 10ml 16ml 
5. Polyvinyl alcohol 1g 4g 
 
Preparation of Domperidone loaded microballoons 
Step 1: Microballoons with an internal hollow structure 
were prepared by emulsion solvent diffusion method with 
slight modification in the method established by Kawashima 
et al (1992).  
Step 2:0.9 gm of Eudragit RS 100, 0.1 gm of HPMC, 
Domperidone (100 mg)was dissolved in mixture of ethanol 
and dichloromethane (2:1). 
Step 3: The polymer solution was slowly introduced into 200 
ml of 0.25% PVA (polyvinylalcohol) aqueous solution at 
40oC; forming an oil-in-water (o/w) type emulsion.  
Step 4: The resultant emulsion was stirred. 
Step 5: The finely disperseddroplets of the polymer solution 
of drug were solidified in the aqueous phase via diffusion of 
the solvent. 
Step 6: After agitating the system for 30 min, the resulting 
polymeric particulate systems were dried overnight at 40oC 
to produce microballoons. 
 
Table No. 3: Formula for different batches for formulation of Domperidone Micro balloons 
Sr.No. Ingredients 
name(mg) 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
1 Domperidone 20 20 20 20 20 20 20 20 20 
2 Ethanol 5 5 5 5 5 5 5 5 5 
3. Dichloromethane  10 10 10 10 10 10 10 10 10 
4. HPMC 1.5 1 0.5 1.5 1 0.5 1.5 1 0.5 
5. Eudragit RS 1.5 1.5 1.5 1 1 1 0.5 0.5 0.5 
6. Polyvinyl alcohol(%) 25 25 25 25 25 25 25 25 25 
 
 
EVALUATION OF MICRO BALLOONS: 
In vitro Dissolution  
The release rate of hollow microspheres are determined in a 
United States Pharmacopoeia (USP) XXIII basket type 
dissolution apparatus.  
A weighed amount of hollow microspheres (filled into a hard 
gelatin capsule) equivalent to dose of drug and place in the 
basket of dissolution rate apparatus containing dissolution 
medium. The dissolution fluid is maintained at 37 ± 1 °C and 
rotation speed at a specific rpm. Perfect sink conditions carry 
out during the drug release study. Few ml (5 ml) of samples 
are withdrawn at each time interval and analyzes using 
Liquid chromatography / Mass spectroscopy method to 
determine the concentration of microballoons present in the 
dissolution medium. The initial volume of the dissolution 
fluid is maintained by adding 5 ml of fresh dissolution fluid 
after each withdrawal. All experiments are run in triplicate11. 
Acceptance criteria-  In acidic stage 10 % drug release and  
phosphate buffer stage drug release NLT 70%                       
  Dissolution at acid medium- 
              Media:                            0.1N HCl 
              Apparatus:                    USP II    apparatus (paddle) 
              RPM:                               75 RPM 
              Amount of media:      1000ml 
              Temperature:               37°C 
              Time:                               up to 2 hr 
              Temperature:               37°C 
              Time:                               up to 8 hr  
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Buoyancy  
Microballoons (100 mg) were dispersed in solution 
composed of HCl and NaCl (300 ml, pH 1.2, 370C) containing 
Tween 20 (0.02 w/v %) to simulate gastric fluid. 
The mixture was stirred witha paddle at 100 rpm. After 12 h, 
the layer of buoyant particles was pipetted and the floating 
particles were separated by filtration. 
Particles in the sinking particulate layer were separated by 
filtration. 
Both particles types were dried at 40oC overnight. 
Each weight was measured and buoyancy was determined by 
the weight ratio of the floating particles to the sum of floating 
and sinking particles. 
 
Buoyancy (%) =         Qf          x   100 
                                                Qf + Qs 
 
Here Qf and Qs are the masses of the floating and settled 
hollow microspheres, respectively. 
Acceptance criteria 95-110% 
 
Entrapment Efficiency and Percentage buoyancy 
Entrapment efficiency of formulated microballoons was the 
function of process variables as well as physiochemical 
properties of drug. It was observed that variation in polymer 
concentration influenced the entrapment efficiency. Increase 
in Eudragit RS100 concentration resulted in increase in 
entrapment efficiency and it was found highest for MB-II e.g. 
84.28. Drug entrapment efficiency was found to be decreased 
with increasing HPMC concentration, because of hydrophilic 
nature of HPMC. Solubility of drug in the organic solvents 
played an important role in determining the drug 
entrapment within micoballoons. Selected drug 
Domperidone was freely soluble in dichloromethane and 
sparingly soluble in ethanol and because of lipophilic 
nature of Domperidone its leaching into PVA aqueous phase 
was minimum and drug entrapment was high. 
The floating test was carried out to investigate the 
floatability of the prepared microballoons. 
Results of buoyancy study were that all the formulations 
showed good floating ability. MB-II formulation shows 76.2% 
of the particles kept floating for at least 12 h. 
Acceptance criteria- 98-110% 
 
 
 
 
 
 
 
 
RESULT AND DISCUSSION 
Table No. 4: Results of Domperidone for Entrapment 
Efficiency, Drug content and Buoyancy study in percent.       
Batch code EE% DC% Buoyancy% 
F1 16.26 2.81 56 
F2 55.53 7.3 89 
F3 68.35 8.31 63 
F4 78.05 8.82 86 
F5 47.01 5.89 61 
F6 81.38 9.42 91 
F7 30.96 4.27 82 
F8 77.57 8.66 84 
F9 47.18 6.82 79 
 
CONCLUSION 
In the present research work systematic evaluation were 
carried out and control strategies were identified in 
manufacturing of micro balloons of Domperidone capsule 
using modern concept of development i.e. Quality by design 
successfully. Important quality control parameters such as 
buoyancy, entrapment efficiency and drug content in 
finished product before and after stability testing were 
remarkably within specified limits of specification. 
Hence, the product manufactured was stable and 
information generated with respect to its manufactured will 
add up to knowledge of micro balloon formulation 
development. 
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